Core Laboratories (CLB) Reports In-Line Q2 EPS, Offers Q4 Guidance

Core Laboratories (NYSE: CLB) reported Q2 EPS of $0.35, in-line with the analyst estimate of $0.35. Revenue for the quarter came in at $148.1 million versus the consensus estimate of $146.4 million.

GUIDANCE:

Core Laboratories sees Q3 2016 EPS of $0.39-$0.41, versus the consensus of $0.41. Core Laboratories sees Q3 2016 revenue of $148-151 million, versus the consensus of $149.4 million.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.

You May Also Be Interested In

• Delta Air Lines stock climbs on earnings beat and strong guidance
• Penguin Solutions (PENG) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY26 EPS Guidance
• Intel (INTC) Price Target Raised to $120 by Stifel Ahead on Expected Earnings Beat